Level of high-mobility group box 1 in patients with chronic hepatitis B and liver cirrhosis and its clinical significance

Yang XinYing; Kang FuBiao; Ye LiHong; Dai ErHei; Sun DianXing

doi:10.3969/j.issn.1001-5256.2018.09.015

Issue 9

Sep. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(9): 1901-1904

PDF( 1585 KB)

Level of high-mobility group box 1 in patients with chronic hepatitis B and liver cirrhosis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2018.09.015

Department of Infectious Liver Diseases, Bethune International Peace Hospital

Received Date: 2018-04-25
Published Date: 2018-09-20

Abstract

Abstract

Objective To investigate the correlation of serum high-mobility group box 1 (HMGB1) level with hepatic inflammatory activity, liver fibrosis degree, and liver function parameters in chronic hepatitis B patients. Methods A total of 73 patients with chronic hepatitis B and liver cirrhosis were enrolled as subjects. Liver biopsy was performed to determine inflammatory activity and liver fibrosis degree, liver function parameters and serum HMGB1 level were measured, and the correlation between HMGB1 level and other indices was analyzed. The t-test was used for comparison between two groups, and a linear correlation analysis was performed to investigate the correlation between two indices. Results The patients with chronic hepatitis B and liver cirrhosis had a significantly higher HMGB1 level than the healthy control group (29. 46 ± 7. 54 ng/ml vs 16. 86 ± 3. 48 ng/ml, t = 5. 668, P < 0. 01) . The G3-G4 group had a significantly higher HMGB1 level than the G1-G2 group (t = 4. 441, P < 0. 01) , while there was no significant difference in HMGB1 level between the S1-S2 group and the S3-S4 group (t = 0. 658, P > 0. 05) . Serum HMGB1 level was positively correlated with alanine aminotransferase (r = 0. 256 6, P = 0. 028 4) and aspartate aminotransferase (r = 0. 471 9, P < 0. 000 1) , while it was not correlated with albumin or total bilirubin (both P > 0. 05) . Conclusion Serum HMGB1 level is closely correlated with hepatic inflammatory activity.
- hepatitis B, chronic,
- liver cirrhosis,
- HMGB1 protein

FullText(HTML)

References(22)

References

[1]GOODWIN GH, JOHNS EW.Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids[J].Eur J Biochem, 2010, 40 (1) :215-219.

[2]WANG H, BLOOM O, ZHANG M, et al.HMG-1 as a late mediator of endotoxin lethality in mice[J].Science, 1999, 285 (5425) :248-251.

[3]GARDELLA S, ANDREI C, FERRERA D, et al.The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway[J].Embo Rep, 2002, 3 (10) :995-1001.

[4]SEMINO C, ANGELINI G, POGGI A, et al.NK/i DC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1[J].Blood, 2005, 106 (2) :609-616.

[5]PALUMBO R, SAMPAOLESI M, MARCHIS FD, et al.Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation[J].J Cell Biol, 2004, 164 (3) :441-449.

[6]FIUZA C, BUSTIN M, TALWAR S, et al.Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells[J].Blood, 2003, 101 (7) :2652-2660.

[7]HORI O, BRETT J, SLATTERY T, et al.The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin.Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system[J].J Biol Chem, 1995, 270 (43) :25752-25761.

[8]YF L, CM C.Hepatitis B virus infection[J].Lancet, 2009, 373 (3) :582-592.

[9]ALBAYRAK A, UYANIK MH, CERRAH S, et al.Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment[J].Viral Immunol, 2010, 23 (6) :633-638.

[10]UIF A, WANG H, KARIN P, et al.High Mobility Group 1 Protein (Hmg-1) stimulates proinflammatory cytokine synthesis in human monocytes[J].J Exp Med, 2000, 192 (4) :565-570.

[11]SHA Y, ZMIJEWSKI J, XU Z, et al.HMGB1 develops enhanced proinflammatory activity by binding to cytokines[J].J Immunol, 2008, 180 (4) :2531-2537.

[12]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[13]Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline for prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.

[14]GUO JS.The critical importance of diagnosing and treating liver fibrosis[J].J Clin Hepatol, 2018, 30 (1) :16-19. (in Chinese) 郭津生.重视肝纤维化的诊治[J].临床肝胆病杂志, 2018, 30 (1) :16-19.

[15]WEI XH, MA LX, FAN ZP, et al.The difference of cell death biomarker M65 at difference liver fibrosis stages of chronic hepatitis B[J].Int J Virol, 2017, 24 (6) :361-364. (in Chinese) 韦新焕, 马丽霞, 范作鹏, 等.细胞死亡标记物M65在慢性乙型肝炎患者不同肝脏纤维化分组间的差异比较[J].国际病毒学杂志, 2017, 24 (6) :361-364.

[16]LI Y, LU LG.Molecular basis of hepatic fibrosis and current status of its diagnosis and treatment[J].J Clin Hepatol, 2018, 34 (1) :12-16. (in Chinese) 李妍, 陆伦根.肝纤维化的分子基础与临床诊治现状[J].临床肝胆病杂志, 2018, 34 (1) :12-16.

[17]HU YB, HU DP, FU RQ.Correlation between high mobility group box-1 protein and chronic hepatitis B infection with severe hepatitis B and acute-on-chronic liver failure:A meta-analysis[J].Minerva Med, 2016, 108 (3) :268-276.

[18]INKAYA AC, DEMIR NA, KOLGELIER S, et al.Is serum highmobility group box 1 (HMGB-1) level correlated with liver fibrosis in chronic hepatitis B?[J].Medicine, 2017, 96 (36) :e7547.

[19]LI J, WANG FP, SH WM, et al.Enhanced high-mobility group box1 (HMGB1) modulates regulatory T cells (Treg) /T helper 17 (Th17) balance via toll-like receptor (TLR) -4-interleukin (IL) -6 pathway in patients with chronic hepatitis B[J].J Viral Hepat, 2014, 21 (2) :129-140.

[20]GE WS, WU JX, FAN JG, et al.Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells[J].World J Gastroenterol, 2011, 17 (36) :4090-4098.

[21]LIU HB, FAN XG, HUANG JJ, et al.Serum level of HMGB1 in patients with hepatitis B and its clinical significance[J].Chin JHepatol, 2007, 15 (11) :812-815. (in Chinese) 刘洪波, 范学工, 黄建军, 等.乙型肝炎患者血清高迁移率族蛋白-1含量的检测及临床意义[J].中华肝脏病杂志, 2007, 15 (11) :812-815.

[22]LI L, CHEN N, HE L, et al.Significance of P53 and high mobility group box 1 protein in different levels of liver fibrosis in chronic hepatitis B[J].J Cent South Univ:Med Sci, 2015, 40 (11) :1217-1222. (in Chinese) 李莉, 陈念, 何柳, 等.P53和高迁移率族蛋白-1在不同程度慢性乙型肝炎后肝纤维化组织中的含量及其意义[J].中南大学学报:医学版, 2015, 40 (11) :1217-1222.

Relative Articles

[1]	Chenlu HAN, Haijun LIANG, Daokun YANG, Haiyan CHANG, Shuai WEI, Xingwei WANG, Haili GAO. Expression levels of serum high-mobility group box 1， soluble CD163， and prostaglandin E2 in patients with hepatitis B virus-related chronic-on-acute liver failure and their value in predicting prognosis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1130-1135. doi: 10.12449/JCH240610
[2]	Pu MinJing, Zhao HongXian, Bo Chao, Zhou XiangYu, Chen Xia. Role and mechanism of the high-mobility group box 1/Toll-like receptor 9 signaling pathway in intestinal mucosal barrier injury in severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1037-1040. doi: 10.3969/j.issn.1001-5256.2019.05.020
[3]	Zhang PanPan, Wang Song, Meng XiangWei, Hua Rui. A case of chronic hepatitis B with mesenteric vasculitis[J]. Journal of Clinical Hepatology, 2017, 33(2): 334-335. doi: 10.3969/j.issn.1001-5256.2017.02.028
[4]	Zhang QingShan, Zhao SuXian, Ren WeiGuang, Kong Li. Chronic hepatitis B with bile duct hamartomas in the liver: a case report[J]. Journal of Clinical Hepatology, 2017, 33(10): 1990-1991. doi: 10.3969/j.issn.1001-5256.2017.10.029
[5]	Zhang ZeTian, Ji HuiFan, Chen Shuai, Li Xu, Yang WenXuan, Zhang GuoShan, Guo XiaoLin. Clinical cure of chronic hepatitis B: a case report[J]. Journal of Clinical Hepatology, 2016, 32(8): 1578-1579. doi: 10.3969/j.issn.1001-5256.2016.08.030
[6]	Wang Fang, Quan ZuoHua, Yang XingKun, Kou JunFeng, Yun ShengHao, Cai GuoFang, Zhou XinRen. Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1118-1120. doi: 10.3969/j.issn.1001-5256.2016.06.019
[7]	Li PingYing, Yang YongGeng, Ma YingCai, Lu LunGen. Adult chronic hepatitis B with acute lymphoblastic leukemia: a case report and literature review[J]. Journal of Clinical Hepatology, 2015, 31(11): 1894-1896. doi: 10.3969/j.issn.1001-5256.2015.11.031
[8]	Wang RongQi, Nan YueMin. Neutropenia caused by telbivudine in chronic hepatitis B patients: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(2): 273-274. doi: 10.3969/j.issn.1001-5256.2015.02.031
[9]	Zhang DaLi, Zhang Min, Su HaiBin. One case of hepatitis B cirrhosis complicated by rhabdomyolysis[J]. Journal of Clinical Hepatology, 2015, 31(3): 434-435. doi: 10.3969/j.issn.1001-5256.2015.03.028
[10]	Wu LieXiu, Lin ShuMei, Zhang Xi, Zheng ShuQin, Ye Feng, Chen TianYan, Zhao YingRen, Zhang ShuLin. Dynamic changes in B7- H1 expression on peripheral blood mononuclear cells in chronic hepatitis B patients treated with entecavir[J]. Journal of Clinical Hepatology, 2014, 30(9): 929-931. doi: 10.3969/j.issn.1001-5256.2014.09.023
[11]	Li ZePeng, Zhao PengTao, Chi XiaoLing, Xiao HuanMing, Xie YuBao. One case of hepatic cirrhosis with tuberculous pleurisy[J]. Journal of Clinical Hepatology, 2014, 30(1): 74-74. doi: 10.3969/j.issn.1001-5256.2014.01.021
[12]	Ding TiLong, Fan XiuMei, Wang Yong, Huang YiJiang, Ma Yong. Expression of hypoxia-inducible factor-1 α in liver tissues of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(2): 124-127.
[13]	Li Juan, Tian Jie, Han Tao, Wei Su. Chronic hepatitis B with adefovir-associated renal insufficiency: a case report[J]. Journal of Clinical Hepatology, 2012, 28(12): 956-957.
[14]	Hepatobiliary Disease Group, Internal Medicine of Traditional Chinese, China Association of Traditional Chinese Medicine, Expert Consensus of Hepatology, World Federation of Chinese Medicine Societies, Hepatology Group, Chinese Association of the Integration of Traditional and Western Medicine. Guidelines for traditional Chinese medical diagnosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2012, 28(3): 164-168.
[15]	Li ChunXia, Pan HuaiQiang, Li YanJun, Xu GuangHua, Chen YanPing, Feng JiHong, Wei Hua, Ceng QingLei. One case report of occult hepatitis B infection[J]. Journal of Clinical Hepatology, 2012, 28(1): 66-68.
[16]	Liu Mei, Zhang LiLi, Chen Ming, Pan XiuCheng, Li Li. The expression of suppressor of cytokine signaling-1 mRNA in the peripheral blood mononuclear cells of patients with chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2011, 27(5): 500-502.
[17]	Li Man, Ceng ZhenJun, Sun XueHua, Zhu XiaoJun, Zhou ZhenHua, Gao YueQiu. The correlational study of the relationship between the fibrosin expression in peripheral blood and hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(12): 1312-1315+1317.
[18]	Niu ChunYan, Zheng JianYun, Li Lei, Gao BaoHua, Liu Bing, Luo JianMei. The expression and significance of HMGB1 in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(8): 807-809.
[19]	Zhang Zhe, Guo JinSheng. The role of high mobility group box 1 in human liver diseases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1116-1120.
[20]	Gao BaoHua, Wang Wen, Niu ChunYan, Zheng JianYun, Liu Bing, Luo JianMei. The expression of HMGB1 in hepatocellular carcinoma, paracancerous liver tissue and its significance[J]. Journal of Clinical Hepatology, 2011, 27(8): 850-853.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	张倩落，马赟，杨国祥，王宏利，贾庶捷. 安络化纤丸联合硫普罗宁治疗慢性乙型肝炎肝硬化的临床研究. 现代药物与临床. 2024(02): 412-417 .
2.	谢娇娇，何燕芳，马燕花，郭才，郑兰兰. 肝硬化患者血清高迁移率族蛋白B水平变化及其与肠黏膜通透性的相关性. 山东医药. 2024(15): 9-12 .
3.	刘俊香，毕泗朕. 血清GP73、HMGB1、FLP1、sST2与慢性乙型病毒性肝炎患者 HBV-DNA载量、肝功能及肝纤维化标志物的相关性分析. 检验医学与临床. 2023(06): 787-791 .
4.	陆燕夏，唐秀娇，郑成芳，王月琴. 血清ANGPTL2、sVAP-1、HMGB1在慢性乙型肝炎诊断中的价值. 国际检验医学杂志. 2022(11): 1325-1328 .
5.	陈婷婷，储建华，杨丽，周宝勤. HMGB-1、PDGF-BB和PTAR水平对慢性乙型肝炎肝硬化病情程度和疾病预后的评估价值. 现代消化及介入诊疗. 2022(10): 1318-1322 .
6.	徐静，张凤岐，王聪，陈磊，郭锋. 血清miR-223、HMGB1与乙肝患者HBV-DNA载量和肝功能的关系研究. 国际病毒学杂志. 2021(04): 332-335 .
7.	何伟锋. 研究慢性乙型肝炎合并非酒精性脂肪性肝病患者的肝组织纤维化水平与脂质负荷的关系. 名医. 2020(09): 58-59 .
8.	许日新，林俊芳，邓雅丽. 慢性乙型肝炎肝硬化患者微生态制剂联合抗病毒药物治疗效果及机体免疫功能的变化. 慢性病学杂志. 2020(12): 1798-1801 .
9.	杜刚，王永利，冯雅. 腹腔镜下左半肝切除术与恩度联合治疗肝癌患者的效果及对血清HMGB1和TK1水平的影响. 临床和实验医学杂志. 2019(17): 1874-1879 .
10.	邓崇君，陆文烈. 探讨替比夫定与恩替卡韦治疗乙型肝炎病毒感染的临床疗效及对炎症因子的影响. 北方药学. 2019(12): 116-117 .
11.	Chunli TANG，Jiangcun WEI，Zhen XIE，Meiyan QIU，Jiabao MA，Fengxian ZHAO，Hongxia CHEN. Water Extraction Process of Chinese Herbal Compound Man Gan Ning. Medicinal Plant. 2019(06): 60-65 .
12.	姚传霞，汪茂荣. 高迁移率族蛋白-1的生物学特性及其在HBV相关肝病发生、发展和治疗中的作用. 临床肝胆病杂志. 2019(12): 2788-2792 . 本站查看

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2296) PDF downloads(354)

Level of high-mobility group box 1 in patients with chronic hepatitis B and liver cirrhosis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2018.09.015